Share Name Share Symbol Market Type Share ISIN Share Description
Polarean Imaging Plc LSE:POLX London Ordinary Share GB00BF3DT583 ORD GBP0.00037
  Price Change % Change Share Price Shares Traded Last Trade
  -4.00 -5.8% 65.00 599,190 16:35:25
Bid Price Offer Price High Price Low Price Open Price
64.00 68.00 70.50 64.00 68.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.74 -4.60 -4.30 105
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:25 O 100,000 67.00 GBX

Polarean Imaging (POLX) Latest News

More Polarean Imaging News
Polarean Imaging Investors    Polarean Imaging Takeover Rumours

Polarean Imaging (POLX) Discussions and Chat

Polarean Imaging Forums and Chat

Date Time Title Posts
26/2/202121:18Polarean Imaging PLC787

Add a New Thread

Polarean Imaging (POLX) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Polarean Imaging trades in real-time

Polarean Imaging (POLX) Top Chat Posts

Polarean Imaging Daily Update: Polarean Imaging Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker POLX. The last closing price for Polarean Imaging was 69p.
Polarean Imaging Plc has a 4 week average price of 63.50p and a 12 week average price of 59p.
The 1 year high share price is 82p while the 1 year low share price is currently 17.45p.
There are currently 161,894,135 shares in issue and the average daily traded volume is 460,192 shares. The market capitalisation of Polarean Imaging Plc is £105,231,187.75.
gregb: IG spread bets now requires 100% margin on POLX and many more companies. Perhaps this is having an effect on the share price?
markstevenkirby80: What could this share price go to once they get FDA approval
acuere: All credit to Genericname on the LSE for this summary of POLX. Here is a brief overiew of Polx Jonathan Allis (Non Executive Chairman) has succesfully been through the FDA approval process with his company Blue Earth which he then sold on to Bracco for $450 million dollars. The market for Polarizers is huge in comparison. Bracco a major global diagnostics company are invested in Polarean and Cyrill Petit who is Chief Corporate Development Officer and Head of Strategic Initiatives of the Bracco Group is now a Non-Executive Director at Polarean. MRI machines emit radiation and can only provide still images. The Polarisers strengthen the MRI signal by 100000 times which enables scanning down to the smallest of bronchioles which is just not possible with an MRI machine alone. Furthermore the Polariser will prevent the patient from becoming exposed to radiation. Systems sale price - $475k Profit margin on systems sale - $285k Price paid to Polx per Xenon dose - $240 Profit per dose of Xenon - $170 Annual servicing contract - $40k Profit on servicing - $20k Software sales per annum - $50k Profit on software $45000 For every 100 machines sold this will generate a recurring, yes every year profit of 12.7 million USD. Not to forget the 47.5 million USD in sales of the machines for every 100 sold.
hedgehog 100: The closer we get to the FDA approval (effectively a licence to sell generally in the US), the more keenly will mass sales of POLX's technology be anticipated. From a December 2018 Northland Capital broker note on POLX: "“Polarean expects over US$500mln in system sales just to top-tier institutes,” said Alexandre in a note to clients." That's why you tend to find that a share price will appreciate a lot during the FDA approval process, in anticipation of the approval. A good relatively recent example is Shield Therapeutics (STX). STX rose about six-fold in the first seven months of last year, from about 30p, until just after its FDA approval on 26th. July 2019. And it more than trebled during this period ahead of the FDA approval, before enjoying a very strong rise at the FDA approval itself. 26/07/2019 07:00 UKREG Shield Therapeutics PLC FDA approves Feraccru® with a broad label "London, UK, 26 July 2019: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency, announces that the U.S. Food and Drug Administration (FDA) has approved its lead product Feraccru(R) / Accrufer(R) for the treatment of iron deficiency in adults. With this broad label approval Accrufer(R) (as the product will be marketed in the USA) has taken a big step towards exploiting the very large commercial opportunity in the USA, the world's largest and most attractively reimbursed pharmaceutical market. Market research suggests that the prescription market for iron replacement therapy in the USA is worth over $1.0bn annually. There are between 8 million and 9 million patients in the USA who suffer from iron deficiency anaemia and management estimate potentially two to three times this number require treatment for iron deficiency. ..."
loglorry1: It's very hard to estimate the value here while still in the development phase but with approval I see no reason why it should not be at £300-500m market cap. If you look at similar (especially US based) companies with healthcare tech some of which hasn't nearly the same potential as POLX they trade at higher than this. Even with a bit of dilution to scale up we are looking at 3x-5x from the current share price.
hedgehog 100: "LSE % Gainers Top Lists EPIC Name % VRP Verona Pharma +118%" Yesterday's top riser VRP illustrates the strong demand for quality lung healthcare shares at the moment: 17/07/2020 07:00 UKREG Verona Pharma plc Verona Pharma Raises $200 Million In Oversubscribed Private Placement And Subscription "LONDON and RALEIGH, N.C., July 17, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it has raised approximately $200 million (GBP159 million*) in an oversubscribed private placement and subscription with new and existing institutional and accredited investors (the "Financing"). The Financing comprises a private placement of 39,090,009 of the Company's American Depositary Shares ("ADSs"), each representing eight ordinary shares of the Company ("Ordinary Shares"), at a price of $4.50 per ADS, and 43,111,112 of the Company's Ordinary Shares at the equivalent price per Ordinary Share, being GBP0.45 or $0.5625 (together the "Securities"). ... Verona Pharma intends to use the net proceeds from the Financing primarily to fund its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) in chronic obstructive pulmonary disease (COPD) and for general corporate purposes. The Phase 3 clinical trials are planned to start later in 2020. ..." With its enlarged equity VRP is now valued at £100s of millions, at its current share price of 101.5p. But it still faces the hurdle of phase three clinical trials, which POLX passed in January of this year with flying colours.
hedgehog 100: It's interesting to compare POLX with AVCT, another COVID-19 play. Coincidentally, both raise funds at a placing price of 18p this spring, within a few weeks of each other: 13/03/2020 12:51 UK Regulatory (RNS & others) Polarean Imaging PLC Conditional Fundraise to raise GBP8.4 million "... GBP8.4 million (US$10.7 million) (before expenses) to be raised by means of a conditional fundraise (the "Fundraise") and the issue of, in aggregate 46,624,997 Fundraise Shares at 18 pence per Fundraise Share (the "Fundraise Price"). ..." 06/04/2020 07:00 UK Regulatory (RNS & others) Avacta Group PLC Proposed Placing to raise GBP3.75 million "...the Company has today conditionally raised gross proceeds of GBP3.75 million pursuant to a placing (the "Placing") through the issuance of 20,833,333 new ordinary shares ("Ordinary Shares") at a price of 18 pence per share, being the same price as the Subscription. ..." Since then AVCT has traded at over 200p per share, and is currently at 139p - a market cap. of £346M. Compared to POLX at 33p - a market cap. of a mere £54M. Although I would expect that to increase markedly this summer, with some key newsflow anticipated this quarter: • New orders to be announced shortly (currently being finalised). • FDA submission. • FDA expediated review news within 45 days of submission. And the closer we get to the FDA approval (effectively a licence to sell generally in the US), the more keenly will mass sales of POLX's technology be anticipated. From a December 2018 Northland Capital broker note on POLX: "“Polarean expects over US$500mln in system sales just to top-tier institutes,” said Alexandre in a note to clients."
hedgehog 100: POLX also featured in a new Vox Markets video yesterday: "Polarean Imaging, Bezant Resources and Paul Hill Justin Waite Vox Markets Podcast with Justin Waite 13:14, 19th June 2020 ... Richard Hullihen, Chief Executive Officer of Polarean Imaging (POLX) discusses the highlights from their final results and talks about the outlook over the next twelve months. Polarean, Inc. are revenue generating, medical drug-device combination companies operating in the high resolution functional magnetic resonance imaging market. The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs. The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion. ..." HTTP:// Here are a few extracts (not quoted verbatim): • POLX's technology is the tool that's been missing in pulmonary medicine. • The existing technology struggles to elucidate pulmonary operation. • POLX's technology is obviously needed so much for COVID-19. • Passing the phase III clinical trials was the biggest achievement this year: a major milestone: unambigious success - couldn't be happier re. • FDA review timing from submission to approval: ten months, + 2 months for the Hatch Waxman (exclusivity) request. • There is some chance that the FDA approval process may finish sooner in the current COVID-19 environment. • POLX will also be looking at the possibility of an expedited FDA review. • Research users will inform and drive this expedited review request. • The vaccines and anti-viral sides of COVID-19 are being speeded up, so the diagnostics side should also be speeded up. • The next big milestone will be the FDA application submission. • POLX also has new orders to announce shortly, as soon as they are papered up. • Three good reasons to add POLX to a watchlist? i. POLX's technology is the ideal solution to a huge unmet need in medicine. ii. POLX's technology is all derisked. About US$60M. has been spent commercialising it. iii. Great management team and board with specialist expertise in the field.
hedgehog 100: A new POLX video interview was posted on Proactive Investors yesterday: "Polarean Imaging in commercial launch mode for its lung function scanner Andrew Scott 07:18 Fri 19 Jun 2020 Polarean Imaging PLC's (LON:POLX) Richard Hullihen caught up with Proactive London's Andrew Scott following a recent pre-NDA meeting with the FDA. He says they're targeting the third quarter of this year to submit an NDA for its drug-device combination which uses hyperpolarised 129-Xenon gas MRI. By inhaling and holding a small amount of the gas for just a few seconds, the patient is able to create a much stronger MRI signal, providing doctors with multiple images of lung structure and function." Here are a few extracts (not quoted verbatim): • The pre-NDA meeting went pretty much as POLX expected. • No delays encountered re. Q3 FDA submission plan. • POLX's drug-device combination is being managed by the drug side of the FDA. • POLX are also seeking a FDA regulatory grant of market exclusivity in the US. • POLX are still selling & installing research equipment - they have an active pipeline - they'll be making a couple of announcements on that in due course. • POLX have non-research target customers for when FDA approval received. • POLX are already preparing for non-research commercial launch. • POLX are excited to be bringing pulmonary medicine in the US into the 21st. century.
diversification: Share register rebalanced Fantastic results today, and while these results were expected the main news today is that the market seems to of filtered out some of the traders and profit takers which was really good to see. Too much hot money is not necessarily a good thing, a sustainable long term uptrend is far more appealing. Funding Recent director purchases would have provided a base to the current share price, as for Allis to have continued to build a sizable position in the company knowing the companies forward cash position, surely if a sizable placing was planned he could of just participated in that. It is also worth noting that the CEO has insisted in the past that the company cash burn is very little following the expensive phase III trial which should see the company through to approval. Strategic partnerships Today’s read out is a key milestone for the company to enable it to enter strategic partnerships which in itself would resolve any funding concerns. NDA Monday this week I contacted investor relations to help clarify priority FDA reviews and Hatch Waxman. I am waiting a response as it was implied that Richard was very busy this week and it may take a couple of days to reply. Conclusion (in my opinion) Imo something significant is being worked on in the background that has led the company directors to build on their own position in the free market. Allis will be only to aware of the potential of this company following the sale of Blue Earth D which means that he has unfinished business in building a more significant stake in POLX. Relatively low forward cash burn enables the company to go into the next 18 months with a relatively clear path to market which can give current shareholders certainty about forward dilution. To consider a small raise would not be the end of the world but I think the company will naturally clarify its forward position in the not to distant future. NDA application, strategic partnerships and further sale of goods for research purposes (funding through grants, which enables the company to have a clear view of forward order book), will all contribute towards future funding and will be significant share price catalysts as it’s the unknowns that the market will struggle to price in. Between now and FDA approval, the free float will continue to shrink which will intensify and future forward moves. I have seen many stocks that have seen a continuation of an upwards trend in anticipation of FDA approval over a longer period of time (STX) and also over a shorter period of time just before FDA results. I see no reason for this to be any different, other than the fact that this is a computer v computer which will help increase the probability of success. None of which is currently priced in, but prior to what could/should be FDA approval and commercialization would see a market cap in excess of £100m which in itself is a share price of 87p or a 170% increase on today’s price which would be more than conservative knowing the commercial numbers, even for a pre-approved application at this stage of its lifecycle.
Polarean Imaging share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Polarean I..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210301 02:12:31